PI16 Antibody

What is PI16 and why is it relevant for research?

PI16 (Peptidase Inhibitor 16) is a member of the CRISP family of proteins expressed by cardiomyocytes, serving as an autocrine negative growth regulator. This transmembrane protein has significant research interest due to its variable molecular weight characteristics and potential roles in inflammatory conditions. Mouse PI16 is a type I transmembrane protein 469 amino acids in length, with only the C-terminal 21 amino acids residing intracellularly . The protein has gained increasing attention following research linking it to inflammatory pain mechanisms via regulation of CD206+ myeloid cells . Understanding PI16's function requires reliable antibodies for detection and characterization across multiple experimental platforms.

Why does PI16 demonstrate anomalous molecular weight on SDS-PAGE?

PI16 exhibits unusual migration patterns in SDS-PAGE, appearing at approximately 70 kDa in its unmodified form despite having a predicted molecular weight of approximately 49-50 kDa . With glycosylation, PI16 can appear at 100-110 kDa . This discrepancy between calculated and observed molecular weights is a critical consideration when performing Western blot validation. Researchers should anticipate multiple band patterns depending on the sample type, processing conditions, and potential post-translational modifications. When planning experiments, it's advisable to run appropriate positive controls such as SKOV-3, A2780, COLO 320, or A549 cells, which have been documented to express detectable levels of PI16 .

What forms of PI16 exist in biological systems?

PI16 exists in both membrane-bound and soluble forms in biological systems. The primary form is a type I transmembrane protein, but soluble variants have been documented . Three potential variants have been identified in mouse models: one showing a deletion of amino acids 51-124, a second with a 9-amino acid extension at the N-terminus, and a third demonstrating a deletion of amino acids 191-452 . These structural variations create complexity for antibody-based detection methods and should be considered when interpreting experimental results.

How should I select the appropriate PI16 antibody for my specific application?

Selection of the appropriate PI16 antibody depends primarily on your experimental application and target species. For Western blot applications, antibodies such as 30527-1-AP (human, rat) and 12267-1-AP (human, mouse) have been validated and offer suitable reactivity profiles . For immunohistochemistry applications, 12267-1-AP has shown positive detection in human liver cancer tissue, human pancreas cancer tissue, and mouse testis tissue .

When selecting an antibody, consider:

• Target species compatibility (human, mouse, rat, etc.)

• Validated applications (WB, IHC, IF/ICC, ELISA)

• Clonality (polyclonal vs. monoclonal)

• Recognition epitope (especially important if studying specific domains or variants)

The optimal antibody will demonstrate consistent, specific staining patterns in your target tissue or cell line with minimal background.

What validation steps should I perform before using a PI16 antibody?

Prior to conducting full-scale experiments, comprehensive validation of PI16 antibodies is essential. The following protocol is recommended:

• Positive control testing: Validate using known positive samples such as SKOV-3, A2780, COLO 320, or A549 cells for human samples, or appropriate tissues for animal models .

• Antibody titration: Perform a dilution series to determine optimal concentration (typically 1:500-1:2000 for WB, 1:50-1:500 for IHC) .

• Blocking peptide controls: Where available, use specific blocking peptides to confirm binding specificity.

• Knockout/knockdown validation: If possible, test antibody specificity using PI16 knockout or knockdown samples.

• Cross-reactivity assessment: Test potential cross-reactivity with related proteins, particularly other CRISP family members.

These validation steps will ensure confidence in subsequent experimental results and facilitate troubleshooting if issues arise.

What are the recommended protocols for Western blotting with PI16 antibodies?

For optimal Western blot detection of PI16, follow these methodological guidelines:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Include both glycosylated and deglycosylated samples if studying post-translational modifications

• Gel selection and transfer:

  • Use 10-12% polyacrylamide gels due to PI16's anomalous migration pattern

  • Transfer to PVDF or nitrocellulose membranes at 25V overnight for optimal results

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Dilute primary antibody according to manufacturer recommendations (typically 1:500-1:2000)

  • Incubate overnight at 4°C with gentle rocking

• Detection considerations:

  • Anticipate bands at both ~49 kDa (calculated weight) and ~70-110 kDa (observed weights)

  • For weakly expressed samples, consider enhanced chemiluminescence or fluorescent detection systems

Careful attention to protocol optimization will help resolve the multiple molecular weight forms of PI16 that may be present in your samples.

What are the recommended protocols for PI16 immunohistochemistry?

For successful PI16 immunohistochemistry, consider the following protocol adaptations:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissue sections (4-6μm thickness)

  • Antigen retrieval is crucial - use TE buffer pH 9.0 (preferred method) or citrate buffer pH 6.0 as an alternative

• Antibody incubation:

  • Dilute antibody within the recommended range (1:50-1:500)

  • Incubate overnight at 4°C in a humidified chamber

  • Use appropriate detection systems (HRP/DAB, fluorescent secondary antibodies) according to experimental design

• Controls:

  • Include known positive tissues (e.g., human liver cancer, human pancreas cancer, mouse testis)

  • Use appropriate blocking sera to reduce non-specific binding

The staining pattern may vary depending on tissue type and PI16 expression levels, requiring optimization for each experimental system.

Why might I observe multiple bands or unexpected molecular weights in my PI16 Western blot?

Multiple bands or unexpected molecular weights in PI16 Western blots can result from several factors:

• Post-translational modifications: PI16 undergoes glycosylation that can increase its apparent molecular weight from the predicted 49 kDa to 100-110 kDa .

• Protein variants: The three known variants of PI16 with amino acid deletions or extensions may produce bands of different sizes .

• Proteolytic processing: As PI16 exists in both membrane-bound and soluble forms, proteolytic cleavage can generate fragments of varying sizes.

• Protein denaturation conditions: Incomplete denaturation can result in dimeric or oligomeric forms appearing as higher molecular weight bands.

To address these issues:

• Include deglycosylation controls (PNGase F treatment) to confirm glycosylation status

• Use reducing and non-reducing conditions in parallel

• Test multiple antibodies recognizing different epitopes

• Consider sample preparation modifications to minimize proteolytic degradation

How can I optimize antibody storage conditions to maintain reactivity?

Proper storage of PI16 antibodies is crucial for maintaining reactivity and experimental reproducibility. Based on manufacturer recommendations:

• Storage temperature:

  • Store at -20°C for long-term storage (12 months from receipt)

  • Short-term storage (up to 1 month) at 2-8°C is acceptable after reconstitution

  • Avoid repeated freeze-thaw cycles by preparing single-use aliquots

• Storage buffer considerations:

  • Most commercial antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Maintain sterile conditions after reconstitution

• Handling guidelines:

  • Allow antibodies to equilibrate to room temperature before opening

  • Centrifuge briefly before opening to ensure all liquid is at the bottom of the vial

  • Return to storage promptly after use

Following these storage recommendations will help maintain antibody performance over time and reduce experimental variability.

What is known about PI16's role in inflammatory conditions?

Recent research has implicated PI16 in inflammatory pain mechanisms, specifically through the regulation of CD206+ myeloid cells . Fibroblast-derived PI16 has been shown to sustain inflammatory pain, suggesting potential therapeutic applications for PI16-targeting strategies. The mechanistic aspects of PI16's function in inflammation remain an active area of investigation, with researchers utilizing PI16 antibodies for detection in tissue homogenates and whole tissue samples .

Additionally, PI16 expression has been associated with muscle wasting and cachexia, as demonstrated in a study by Chen et al. (2013) that showed elevated expression of activins promotes these conditions . This connection between PI16 and inflammatory states offers promising research directions for conditions characterized by chronic inflammation and tissue degeneration.

How can PI16 antibodies be implemented in multi-marker immunofluorescence studies?

For complex tissue analyses requiring multiple marker detection, PI16 antibodies can be integrated into multiplex immunofluorescence protocols:

• Antibody selection considerations:

  • Choose PI16 antibodies raised in different host species than other target antibodies

  • Verify that secondary antibodies do not cross-react

  • Consider directly conjugated antibodies when available

• Staining sequence optimization:

  • Test sequential versus simultaneous antibody incubation

  • Determine optimal antibody concentration through titration (1:200-1:800 for IF/ICC applications)

  • Include appropriate blocking steps between antibody applications

• Signal amplification strategies:

  • Consider tyramide signal amplification for weakly expressed targets

  • Optimize exposure settings to balance signals between markers

PI16 has been successfully detected in immunofluorescence applications using antibodies such as 30527-1-AP in cell lines including SKOV-3 , suggesting compatibility with multi-marker approaches.